<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940586</url>
  </required_header>
  <id_info>
    <org_study_id>8228-030</org_study_id>
    <secondary_id>2018-001326-25</secondary_id>
    <secondary_id>MK-8228-030</secondary_id>
    <secondary_id>205242</secondary_id>
    <nct_id>NCT03940586</nct_id>
  </id_info>
  <brief_title>Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)</brief_title>
  <official_title>A Phase 2b Open-label, Single-arm Study to Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth to Less Than 18 Years of Age at Risk of Developing CMV Infection and/or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir
      (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups:
      Age Group 1: From 12 to &lt;18 years of age (adolescents); Age Group 2: From 2 to &lt;12 years of
      age (children); and Age Group 3: From birth to &lt;2 years of age (neonates, infants and
      toddlers). All participants will receive open label LET for 14 weeks (~100 days)
      post-transplant, with doses based on body weight and age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Anticipated">October 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of plasma letermovir for oral formulation</measure>
    <time_frame>Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose</time_frame>
    <description>Area under the curve from time 0 to 24 hours post-dose (AUC0-24) of plasma letermovir during intensive pharmacokinetics (PK), for participants receiving oral formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal concentration of plasma letermovir for oral formulation</measure>
    <time_frame>Day 7: Pre-dose, 1, 2.5, 8, and 24 hours post-dose</time_frame>
    <description>Maximal concentration (Cmax) of plasma letermovir during intensive PK, for participants receiving oral formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration of plasma letermovir observed before next dose for oral formulation</measure>
    <time_frame>Day 7: Pre-dose</time_frame>
    <description>Minimum concentration of plasma letermovir observed before next dose (Ctrough) during intensive PK, for participants receiving oral formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of plasma letermovir for intravenous formulation</measure>
    <time_frame>After 5 consecutive days of administration of intravenous formulation: Pre-dose, 1, 2.5, 8, and 24 hours post-dose (up to 14 weeks)</time_frame>
    <description>Area under the curve from time 0 to 24 hours post-dose (AUC0-24) of plasma letermovir, for participants receiving intravenous (IV) formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at the end of infusion of plasma letermovir for IV formulation</measure>
    <time_frame>After 5 consecutive days of administration of IV formulation: 1 hour post-dose (up to 14 weeks)</time_frame>
    <description>Concentration of plasma letermovir at the end of infusion (Ceoi), for participants receiving IV formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration of plasma letermovir observed before next dose for IV formulation</measure>
    <time_frame>After 5 consecutive days of administration of IV formulation: Pre-dose (up to 14 weeks)</time_frame>
    <description>Minimum concentration of plasma letermovir observed before next dose (Ctrough) during intensive PK, for participants receiving IV formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration of plasma letermovir observed before next dose during sparse PK for oral formulation</measure>
    <time_frame>Pre-dose on Weeks 2, 4, 6, 8, 12, 14</time_frame>
    <description>Minimum concentration of plasma letermovir observed before next dose (Ctrough) during sparse PK, for participants receiving oral formulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum concentration of plasma letermovir observed before next dose during sparse PK for IV formulation</measure>
    <time_frame>Pre-dose on Weeks 2, 4, 6, 8, 12, 14</time_frame>
    <description>Minimum concentration of plasma letermovir observed before next dose (Ctrough) during sparse PK, for participants receiving IV formulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants with an adverse event</measure>
    <time_frame>Up to Week 48 post-transplant (up to 52 weeks)</time_frame>
    <description>Percentage of participants with one or more adverse event (AE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants who discontinued study medication</measure>
    <time_frame>Up to Week 14 post-transplant (up to 18 weeks)</time_frame>
    <description>Percentage of participants who discontinued study medication due to an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with clinically significant CMV infection through Week 14 post-transplant</measure>
    <time_frame>Up to Week 14 post-transplant (up to 18 weeks)</time_frame>
    <description>Percentage of participants with clinically significant CMV infection (CS-CMVi) through Week 14 post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with clinically significant CMV infection through Week 24 post-transplant</measure>
    <time_frame>Up to Week 24 post-transplant (up to 28 weeks)</time_frame>
    <description>Percentage of participants with clinically significant CMV infection (CS-CMVi) through Week 24 post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on a palatability scale for participants receiving oral granules.</measure>
    <time_frame>On the first and eighth day of administration of oral formulation up to Week 14 post-transplant (up to 18 weeks)</time_frame>
    <description>Palatability was measured by a facial hedonic scale (FHS), a five point facial expression scale depicting various degrees of pleasure, where a score of 1 indicated disliked very much; ranging to a score of 5 which indicated liked very much.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cytomegalovirus (CMV) Infection</condition>
  <arm_group>
    <arm_group_label>Letermovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letermovir administered either orally or intravenously within 28 days post-transplant, once daily through week 14 (approximately 100 days). Dosing will vary based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir oral granules</intervention_name>
    <description>Granules administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
    <other_name>AIC246</other_name>
    <other_name>AIC001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir tablet</intervention_name>
    <description>Tablet administered orally based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
    <other_name>AIC246</other_name>
    <other_name>AIC001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letermovir intravenous</intervention_name>
    <description>Letermovir administered intravenously based on age, weight, and whether participant takes cyclosporin A as a concomitant medication.</description>
    <arm_group_label>Letermovir</arm_group_label>
    <other_name>MK-8228</other_name>
    <other_name>AIC246</other_name>
    <other_name>AIC001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants 12 to &lt;18 years old must have documented positive CMV serostatus (CMV
             IgG seropositive) for the recipient (R+). Participants from birth to &lt;12 years old
             must have documented positive CMV serostatus (CMV IgG seropositive) for the recipient
             (R+) and/or the donor (D+) and the time of screening.

          -  Is the recipient of a first allogeneic HSCT (bone marrow, peripheral blood stem cell,
             or cord blood transplant).

          -  Has undetectable CMV DNA from a plasma or whole blood sample collected within 5 days
             prior to enrollment.

          -  Is within 28 days post-HSCT at the time of enrollment.

          -  Females are not pregnant, not breastfeeding,and is not a woman of childbearing
             potential (WOCBP); or is a WOCBP who agrees to follow the contraceptive guidance
             during the treatment period and for at least 28 days after the last dose of study
             intervention.

          -  Participants from 2 to &lt;18 years of age must not be on concomitant Cyclosporin A
             (CsA), and must be able to take LET tablets or the oral granules (either by mouth or
             via G tube/NG tube), provided the participant does not have a condition that may
             interfere with the absorption of oral medication (e.g. vomiting, diarrhea, or a
             malabsorptive condition) from the day of enrollment until the intensive PK sampling is
             completed in these participants

        Exclusion Criteria:

          -  Has received a previous allogeneic HSCT (Note: receipt of a previous autologous HSCT
             is acceptable).

          -  Has a history of CMV end-organ disease within 6 months prior to enrollment.

          -  Has evidence of CMV viremia at any time from either signing of the ICF or the HSCT
             procedure, whichever is earlier, until the time of enrollment.

          -  Has suspected or known hypersensitivity to active or inactive ingredients of LET
             formulations.

          -  Has severe hepatic insufficiency within 5 days prior to enrollment.

          -  Is on hemodialysis or has end-stage renal impairment.

          -  Has both moderate hepatic insufficiency and moderate-to-severe renal insufficiency.

          -  Has an uncontrolled infection on the day of enrollment.

          -  Requires mechanical ventilation or is hemodynamically unstable at the time of
             enrollment.

          -  Has a documented positive result for a human immunodeficiency virus antibody (HIVAb)
             test at any time prior to enrollment, or for hepatitis C virus antibody (HCV-Ab) with
             detectable HCV RNA, or hepatitis B surface antigen (HBsAg) within 90 days prior to
             enrollment.

          -  Has active solid tumor malignancies with the exception of localized basal cell or
             squamous cell skin cancer or the condition under treatment (e.g. lymphomas).

          -  Has a preexisting cardiac condition a) for which the patient is currently being
             treated or b) which required hospitalization within the last 6 months or c) that may
             be expected to recur during the course of the trial.

          -  Has received within 7 days prior to screening any of the following: ganciclovir;
             valganciclovir; foscarnet; acyclovir; valacyclovir; famciclovir.

          -  Has received within 30 days prior to screening of any of the following: cidofovir; CMV
             immunoglobulin; any investigational CMV antiviral agent/biologic therapy; Rifampin and
             other strong inducers (such as phenytoin, carbamazepine, St John's wort (Hypericum
             perforatum), rifabutin and phenobarbital) and moderate inducers such as nafcillin,
             thioridazine, modafinil and bosentan.

          -  Has received LET at any time prior to enrollment in this study.

          -  Is currently participating or has participated in a study with an unapproved
             investigational compound or device within 28 days, or 5X half-life of the
             investigational compound (excluding monoclonal antibodies), whichever is longer, of
             initial dosing in this study.

          -  Has previously participated in this study or any other study involving LET.

          -  Has previously participated or is currently participating in any study involving
             administration of a CMV vaccine or another CMV investigational agent, or is planning
             to participate in a study of a CMV vaccine or another CMV investigational agent during
             the course of this study.

          -  Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from
             the time of consent through 28 days after the last dose of study intervention.

          -  Is expecting to donate eggs starting from the time of consent through 28 days after
             the last dose of study intervention.

          -  Has clinically relevant drug or alcohol abuse within 12 months of screening that may
             interfere with participant treatment, assessment, or compliance with the protocol, as
             assessed by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center ( Site 0251)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>626-218-8442</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County ( Site 0241)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>714-509-4064</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco ( Site 0245)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-476-3833</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Chicago School Of Medicine ( Site 0253)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-1665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital ( Site 0243)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-355-6832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center ( Site 0254)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-639-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Health System ( Site 0252)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-684-6335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0244)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-636-7499</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC ( Site 0258)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-692-7529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center ( Site 0257)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-456-6761</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital ( Site 0248)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-987-2073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children s Hospital at Westmead ( Site 0185)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298452174</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children s Hospital ( Site 0182)</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61730697630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne ( Site 0181)</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61393454893</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto De Cancerologia S.A. ( Site 0213)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050024</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573148898616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0212)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573154896219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A ( Site 0211)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5726821000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt ( Site 0112)</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+496963017126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster ( Site 0114)</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492518347742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin - Campus-Virchow-Klinikum ( Site 0113)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930450666658</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf ( Site 0111)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741052720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center ( Site 0122)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972504057148</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0121)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972502064722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hemato Oncology Safra Children's Hospital, Sheba Medical Center ( Site 0123)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9725066663570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center ( Site 0202)</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81486012200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nuevo Hospital Civil Dr Juan I Menchaca ( Site 0223)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+523335856617</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez ( Site 0222)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+528183486136</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0224)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico ( Site 0221)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525561521239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus ( Site 0151)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hastanesi ( Site 0162)</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322348164</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Faculty of Medicine ( Site 0161)</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902422496872</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Univ.Tip Fakultesi Cocuk Has ( Site 0163)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323902803</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

